Synlett
DOI: 10.1055/a-2541-1072
letter
Small Molecules in Medicinal Chemistry

Synthesis, Characterization and In Vitro and In Silico Biological Evaluation of New Mannich-Based Rhodanine and Thiazolidine-2,4-dione Derivatives as Potential Anti-Lung-Cancer Agents

Şeyma Ateşoğlu
a   Bezmialem Vakif University, Institute of Health Sciences, Department of Biotechnology, 34093 Fatih, Istanbul, Türkiye
b   Bezmialem Vakif University, Faculty of Medicine, Department of Medical Biology, 34093 Fatih, Istanbul, Türkiye
,
Furkan Çakır
c   Bezmialem Vakif University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 34093 Fatih, Istanbul, Türkiye
,
Ayşe Merve Şenol
d   Program of Medical Laboratory Techniques, Department of Medical Services and Techniques, University of Health Sciences, Üsküdar, 34668, Istanbul, Türkiye
,
Pelin Tokalı
e   Department of Veterinary Physiology, Faculty of Veterinary Medicine, Kafkas University, 36100, Kars, Türkiye
,
c   Bezmialem Vakif University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 34093 Fatih, Istanbul, Türkiye
,
Feyzi Sinan Tokalı
f   Kafkas University, Kars Vocational School, Department of Material and Material Processing Technologies, 36100 Kars, Türkiye
,
Fahri Akbaş
b   Bezmialem Vakif University, Faculty of Medicine, Department of Medical Biology, 34093 Fatih, Istanbul, Türkiye
,
Erbay Kalay
f   Kafkas University, Kars Vocational School, Department of Material and Material Processing Technologies, 36100 Kars, Türkiye
› Author Affiliations


Preview

Abstract

In this study, 10 new rhodanine and thiazolidine-2,4-dione derivatives based on Mannich-modified vanillin were synthesized, characterized, and evaluated for their anticancer potential against A549 lung cancer and BEAS-2B normal cells. Among them, compound 5c exhibited the most potent anticancer activity, with an IC50 of 2.43 μM and a selectivity index of 10.91, showing higher selectivity than the reference drug sorafenib. Molecular docking studies suggested 5c as a strong potential epidermal growth factor receptor (EGFR) inhibitor, supported by a docking score of –9.827 kcal/mol and key interactions with residues such as Met-793, Leu-788, and Phe-856. Molecular dynamics simulations further confirmed the stability of the 5c-EGFR complex. ADMET predictions indicated favorable pharmacokinetic and safety profiles for 5c, including high permeability, oral absorption, and no significant toxicity. These findings highlight 5c as a promising lead compound for targeted lung cancer therapy, warranting further preclinical studies.

Supporting Information



Publication History

Received: 27 December 2024

Accepted after revision: 17 February 2025

Accepted Manuscript online:
17 February 2025

Article published online:
08 April 2025

© 2025. Thieme. All rights reserved

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany